Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data releases for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - Revenue for 2025 is projected at RMB 130 million, a 24% year-on-year increase, primarily driven by overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is expected to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is projected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - The report provides updated revenue forecasts for 2026E at USD 85 million, with a gross profit of USD 33 million and a gross margin of 39.3%. The net loss for 2026E is projected at USD 353 million [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of a registrational study for non-small cell lung cancer (NSCLC). Additionally, confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are expected [6][12].

Investment Rating - The investment rating for Anta Sports is "Buy" [6] Core Insights - Anta Sports is expected to achieve a revenue growth of 13.3% to 80.219 billion yuan in 2025, with a net profit growth of 13.9% after excluding one-time gains [1] - The company emphasizes shareholder returns with a dividend payout ratio of 50.1% [1] - The brand strategy focuses on multi-brand operations, with significant growth expected from the Fila brand and other outdoor brands [4][11] Revenue Summary - Anta brand revenue is projected to grow by 3.7% to 34.754 billion yuan in 2025, with direct-to-consumer (DTC) channels showing positive growth [2] - Fila brand revenue is expected to increase by 6.9% to 28.469 billion yuan, demonstrating resilience in a fluctuating market [4] - Other brands, including Descente and Kolon Sport, are forecasted to grow by 20% to 30% in 2026, with Descente's revenue expected to exceed 10 billion yuan [11] Profitability Summary - Anta brand's operating profit margin is stable at 20.7%, despite a slight decline in gross margin to 53.6% due to increased product costs [3] - Fila brand's operating profit margin improved to 26.1%, reflecting effective cost management despite a decrease in gross margin to 66.4% [5] - Overall, the company maintains a high-quality growth trajectory with a net profit margin of 16.9% in 2025 [1] Financial Projections - The projected net profit for Anta Sports in 2026 is approximately 14.053 billion yuan, with a revenue growth forecast of high single digits [13] - The expected earnings per share (EPS) for 2026 is 5.60 yuan, with a price-to-earnings (P/E) ratio of 13 times [14] - Long-term projections indicate a net profit of 17.627 billion yuan by 2028, with a consistent growth rate [14]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5]. Core Insights - The company reported a significant decline in revenue and net profit for 2025, with revenue at 3.65 billion yuan, down 48.3% year-on-year, and net profit at 538 million yuan, down 59.3% [2]. - The company is focusing on the "Wanshang Alliance" model and expanding its equity payment plan to other product series, aiming to capture new consumer demand and optimize distribution channels [4]. Financial Performance - In 2025, the company achieved revenue of 3.65 billion yuan, with a year-on-year decline of 48.3%. The adjusted net profit was 5.23 billion yuan, down 68.8% [2][10]. - For the second half of 2025, revenue was 1.15 billion yuan, a decrease of 60.7%, with a net loss of 36 million yuan [2]. - The revenue breakdown by product for 2025 shows significant declines: Zhenjiu at 1.92 billion yuan (-57%), Liduo at 1.09 billion yuan (-17%), Xiangjiao at 470 million yuan (-42%), and Kaikouxiao at 100 million yuan (-70%) [3]. Future Projections - Revenue projections for 2026-2028 are 3.91 billion yuan, 4.34 billion yuan, and 5.03 billion yuan, representing year-on-year growth rates of 7.1%, 10.9%, and 16.0% respectively [5]. - The expected net profit for the same period is 670 million yuan, 860 million yuan, and 1.14 billion yuan, with growth rates of 24.6%, 28.1%, and 32.3% respectively [5].

Investment Rating - The investment rating for the company is Neutral with a target price of HKD 37.00, indicating a potential upside of 13.2% from the current price of HKD 32.68 [1][3][12]. Core Insights - The company reported a total revenue of RMB 116.9 billion for Q4 2025, representing a year-on-year increase of 7%. However, the adjusted net profit decreased by 24% to RMB 6.35 billion, highlighting ongoing pressure from storage costs [2][8]. - The company is focusing on advancements in AI and other innovative fields, with significant investments planned in AI technologies, including a projected RMB 160 billion in 2026 and a cumulative investment of RMB 600 billion over the next three years [7][2]. - The automotive segment is expected to see substantial growth, with revenue projected to increase by 224% year-on-year to RMB 106.1 billion, and the company aims to sell 559,000 vehicles in 2026 [7][2]. - The AIoT business is also anticipated to grow, with revenue expected to rise by 18% to RMB 123.2 billion, and an improvement in gross margin by 2.8 percentage points to 23.1% [7][2]. Financial Overview - Revenue projections for the company are as follows: RMB 365.9 billion in 2024, RMB 457.3 billion in 2025, RMB 493.2 billion in 2026, RMB 551.0 billion in 2027, and RMB 599.9 billion in 2028, with corresponding year-on-year growth rates of 35.0%, 25.0%, 7.9%, 11.7%, and 8.9% respectively [6][14]. - The adjusted net profit is forecasted to be RMB 23.7 billion in 2024, RMB 41.6 billion in 2025, RMB 33.7 billion in 2026, RMB 40.7 billion in 2027, and RMB 47.5 billion in 2028 [6][14]. - The company’s earnings per share (EPS) is expected to be RMB 1.10 in 2024, RMB 1.53 in 2025, and remain stable at RMB 1.53 in 2026, with a slight increase to RMB 1.73 in 2027 and RMB 1.99 in 2028 [6][14]. Valuation - The company’s valuation is based on a sum-of-the-parts (SOTP) approach, with a projected net profit of RMB 39.7 billion in 2026, leading to a price-to-earnings (P/E) ratio of 21.4 times [10][2]. - The valuation for the mobile and AIoT segments is estimated at RMB 721.8 billion, while the automotive and AI innovation business is valued at RMB 230.9 billion [10][2].

Investment Rating - The report maintains a "Buy" rating for Anta (2020 HK) with a target price of HKD 108.70, indicating a potential upside of 43.5% from the current price of HKD 75.75 [1][2][7]. Core Insights - Anta's revenue for 2025 is projected to grow by 13.3% year-on-year to RMB 80.22 billion, with net profit expected to increase by 13.9% to RMB 13.59 billion, slightly exceeding previous expectations [6][7]. - The company's operational efficiency has shown resilience, with an operating profit margin improvement of 0.4 percentage points to 23.8% despite a slight decline in gross margin [6][7]. - Anta's long-term strategy of "single focus, multi-brand, globalization" remains unchanged, aiming to solidify brand assets and capture greater market share during the industry recovery cycle [6][7]. Financial Summary - Revenue projections for Anta are as follows: - 2024: RMB 70.83 billion - 2025: RMB 80.22 billion - 2026E: RMB 86.10 billion - 2027E: RMB 91.89 billion - 2028E: RMB 97.33 billion - Year-on-year growth rates are expected to be 13.6% for 2024, 13.3% for 2025, 7.3% for 2026, 6.7% for 2027, and 5.9% for 2028 [5][10]. - Net profit forecasts are as follows: - 2024: RMB 15.60 billion - 2025: RMB 13.59 billion - 2026E: RMB 13.93 billion - 2027E: RMB 14.90 billion - 2028E: RMB 16.05 billion [5][18]. Brand Performance - Anta brand revenue is expected to grow by 3.7% year-on-year, while FILA is projected to see a 6.9% increase, focusing on high-end sports fashion [6][7]. - Other brands under Anta have shown strong growth, with a 59.2% increase in revenue, highlighting the resilience of the multi-brand strategy [6][7].

Investment Rating - The report maintains a cautious outlook on Samsonite, indicating potential revenue pressure in the first half of 2026 due to geopolitical tensions and market conditions [3]. Core Insights - Samsonite's Q4 2025 performance did not provide full-year guidance, leading to stock price pressure as the company may face revenue challenges in Q1 and Q2 2026 [3]. - Q1 2026 sales are expected to remain flat year-on-year, driven by growth in China, Japan, and South Korea, but offset by weak European markets and flat North American sales [3]. - The report anticipates a more challenging Q2 with continued geopolitical impacts, although the market has already priced in these expectations [3]. - For 2026, the report forecasts zero growth in sales adjusted for exchange rates, with improvements expected in all regions except Europe [3]. Company Overview - Samsonite International is the world's largest travel luggage company by retail sales, selling products under brands such as Samsonite, Tumi, and American Tourister [7]. - The company has a diversified geographic presence and a decentralized business model, allowing it to develop unique product solutions for various markets [7]. - Continuous brand investment positions Samsonite to benefit from sustained high growth in the global travel industry [7]. Revenue Breakdown - Revenue by product category: Samsonite (52.0%), Tumi (24.0%), American Tourister (16.6%), Others (7.4%) [8]. - Revenue by region: Americas (40.6%), Asia (36.2%), Middle East and Africa (2.4%), Europe (20.8%) [8]. Stock Information - Stock price as of March 25, 2026: HKD 15.21, with a market capitalization of USD 2.7 billion [8]. - Consensus target price from Refinitiv: HKD 24.32 [8].

Investment Rating - The report maintains a "Buy" rating for China COSCO Shipping International (00517) [2][7] Core Views - The company's performance for 2025 met expectations, with revenue of HKD 3.7 billion, a 2% year-on-year increase, and a net profit attributable to shareholders of HKD 771 million, a 9% increase year-on-year [7] - The coatings business shows growth potential, with revenue from coatings production and sales reaching HKD 1.63 billion in 2025, a 22% increase year-on-year, and a segment profit before tax of HKD 430 million, a 31% increase year-on-year [7] - The company is focusing on green methanol production, planning to establish a joint venture with a capacity of 200,000 tons per year, expected to start production in 2026 [7] - The company emphasizes shareholder returns, planning to implement a special dividend, with a payout ratio of 99% for 2025, potentially reaching 118% with the special dividend [7] - The report highlights the company's growth potential and high dividend yield, maintaining the "Buy" rating despite a downward adjustment in revenue growth for the ship spare parts business to 0% for 2026 [7] Financial Summary - Revenue projections for the company are as follows: HKD 3.63 billion for 2026, with a slight decrease to HKD 3.59 billion in 2027 and 2028 [6][9] - Net profit attributable to shareholders is projected to be HKD 822 million for 2026, increasing to HKD 881 million by 2028 [6][9] - Earnings per share are expected to rise from HKD 0.56 in 2026 to HKD 0.60 in 2028, with a price-to-earnings ratio of 12 for 2026 and 11 for 2028 [6][9]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported its 2025 annual results, which met expectations, with revenue of 55.19 billion RMB, a slight decrease of 0.4% year-on-year, and a net profit of 19.15 billion RMB, down 7.1% year-on-year [6] - The medical beauty business is contributing a new growth curve, with the core product line and multiple series matrix continuously improving [6] - The company is focusing on shareholder returns, with a total dividend payout of approximately 1.29 billion RMB for the 2025 fiscal year [6] Financial Data and Profit Forecast - Revenue projections for 2026 are estimated at 60.45 billion RMB, with a year-on-year growth rate of 10% [5] - The net profit attributable to ordinary shareholders is forecasted to be 19.17 billion RMB in 2026, with a growth rate of 0% [5] - The earnings per share (EPS) for 2026 is projected to be 1.79 RMB, with a price-to-earnings (PE) ratio of 14.6 [5] Business Performance - The company's main product, "可复美," generated revenue of 44.7 billion RMB, accounting for 81% of total revenue, despite external shocks and industry competition [6] - The direct sales channel remained stable, with direct revenue of 41.4 billion RMB, representing 74.9% of total revenue [6] - The company is positioned in the collagen protein market, with both "可复美" and "可丽金" brands maintaining high growth rates [6]

Investment Rating - The report assigns a "BUY" rating for the company, indicating a potential upside in the stock price [7][8]. Core Insights - The company achieved a revenue of RMB 80.22 billion in 2025, representing a year-on-year increase of 13.3%. However, the net profit attributable to shareholders decreased by 12.9% to RMB 13.59 billion. Excluding the impact of Amer Sports' listing, the net profit increased by 13.9% year-on-year [8][9]. - The company plans to expand its global operations, aiming to establish 1,000 retail outlets in Southeast Asia by 2028 and entering markets in South Asia, Australia, New Zealand, and India [9]. - The company has made strategic acquisitions, including the purchase of shares in Wolf Claw and PUMA, and invested in the South Korean fashion e-commerce platform MUSINSA, which is expected to enhance its brand portfolio and market coverage [9]. Summary by Sections Company Overview - The company operates in the textile and apparel industry, with a current stock price of HKD 75.75 and a market capitalization of HKD 215.85 billion [2]. Recent Ratings - The company has consistently received "BUY" ratings in recent reports, with the last rating issued on January 27, 2026, at a closing price of HKD 76.35 [3]. Product Mix - The product portfolio consists of footwear (39.3%), apparel (57.1%), and accessories (3.6%) [4]. Financial Performance - The company reported a gross margin of 62% for the reporting period, a decrease of 0.2 percentage points year-on-year, attributed to the rising proportion of lower-margin e-commerce business and increased costs [9]. - The projected net profits for 2026, 2027, and 2028 are RMB 14.6 billion, RMB 16.27 billion, and RMB 18.27 billion, respectively, with corresponding year-on-year growth rates of 7.4%, 11.4%, and 12.3% [9][11]. Dividend Policy - The company announced a cash dividend of HKD 1.08 per share for the reporting period [8].

资负经营稳健，派息超预期 中国太平(0966) ——中国太平 2025 年年度业绩点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 刘欣琦(分析师) | 021-38676647 | liuxinqi@gtht.com | S0880515050001 | | | | 李嘉木(分析师) | 021-38038619 | lijiamu@gtht.com | S0880524030003 | [当前价格 Table_CurPrice] (港元)： | 21.18 | 本报告导读： 公司 25 年归母净利润同比 220.9%，主要由新企业所得税政策一次性影响导致;25 年 分红 1.23 港元/股，同比 251.4%; NBV 小幅增长，财险 COR改善，权益配置提升。 投资要点： | 请务必阅读正文之后的免责条款部分 | | --- | 研 究 股票研究 /[Table_Date] 2026.03.26 | | | [Table_Industry] ...